Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We've made tremendous progress, not just in pancreatic cancer, but also in advanced recurrent ovarian cancer and Stage 4 triple-negative breast cancer where we're seeing dramatic clinical impacts with Ampligen |
| The pipeline is strong, and there are a number of other clinical trials that are underway that you can see in detail and Dr |
| And from a scientific and clinical perspective, I think stockholders should be excited about the short-term and long-term future of AIM, and potentially the patients can be excited about future therapy |
| We have a growing body of highly encouraging positive clinical data with Ampligen in several high-value important indications of significant, often legal, unmet medical needs |
| We're very proud of our accomplishments and the accomplishments of our collaborators as we go forward |
| So I think they'll -- goes to my previous statement that the AMP-270 might respond better, even better than what we have from the EAP |
| We believe what we are witnessing now in our later-stage clinical studies not only gives us confidence in our lead programs, but also a line of sight into the broad utility we believe Ampligen possesses |
| So we're -- we got the best of the best working on these projects and helping us to move forward |
| We are grateful for your time today, and we believe we are well positioned for an exciting 2024 and beyond |
| Our team at AIM continues to build on a solid foundation, fundamentally driving AIM forward |
| We are also involved in a strategy to further engage with industry for licensing partnerships and M&A opportunities, which we believe has the opportunity and the potential to unlock significant value as we continue to expand our reach across the investment community to garner further validation and support from what we believe represents an exciting investment opportunity |
| We have had great progress over the past 18 months |
| So the more subjects we've had, the better the survival -- progression-free survival and overall survival data gets |
| Great job articulating the clinical progress we've made in fine detail |
| We are very much looking forward to pursuing and heightening this momentum in 2024, and providing -- and this is perhaps the most important thing to us, providing hope and opportunity for patients who have unmet medical needs in these serious diseases |
| And these data again are promising because they show Ampligen containing therapies can modulate the tumor microenvironment to create a more hot tumor state |
| And this study provides us with a unique opportunity and how we navigate that opportunity from a regulatory strategy is still being discussed |
| So these things are all good |
| Now our pipeline, and this addresses just a few of the major things on our pipeline, is extensive, and we've been laying down a lot of important data over the past year, data that supports the proposition that we have extremely good potential in oncology |
| So we have high hopes and reasonable, but optimistic expectations as to the progress we'll make |
| In pancreatic cancer we believe we'll be seeing significant progress in the United States as well because of the expansion of the sites, and we're expecting the data from the post-COVID trial |
| And to that point, the overall survival short term and long term seem to actually improve with the addition of the patients over those historical controls |
| McAleer will talk to the data, but it's been increasingly positive |
| Based on the extensive and consistently positive clinical progress, we've had to give it a priority space in our lineup |
| And so, with all the initial enrollment is imminent at any point in this juncture in AMP-270, and I think with the additional sites opening in the next few months, we hope for patient recruitment to increase exponentially |
| 2022 was a spectacular year in terms of our clinical development and the first three quarters of this year have been in touch with that same level of progress as we move forward towards multiple value-driving milestones |
| We have never before been more confident in the potential of Ampligen and our ability to work globally with regulatory bodies to ultimately bring Ampligen to patients in need |
| And it's unique because it's a toll-like receptor agonist which stimulates the immune system and has immunomodulatory qualities, but it's very unique and somewhat rare because it does not have the systemic inflammation that other TLR drugs show |
| But anybody who's familiar with deals in biotech knows the volume of deals and the value of deals is extremely high in the oncology space |
| So our ability to move forward is unimpaired and we intend to move forward as rapidly as possible with our clinical undertakings, because it is through data that we create long-term stockholder value |
| Statement |
|---|
| The price of the Ampligen -- the cost of the Ampligen would drop significantly if it were picked up by a company that was in a position to make large amounts of Ampligen |
| As you manufacture this 10,000 vial lock, is the cost about the same as it was before? Has it gone up? Has it gone down? Thomas Equels Unfortunately, inflation has an even greater toll in our industry |
| So we can't be mistaken |
| These are forward-looking statements and involve risks and uncertainties |
Please consider a small donation if you think this website provides you with relevant information